Steven D. Rubin - Jan 30, 2023 Form 4 Insider Report for Eloxx Pharmaceuticals, Inc. (ELOX)

Role: Director
Signature: /s/ Sumit Aggarwal, Attorney-in-Fact for Steven D. Rubin
Stock symbol: ELOX
Transactions as of: Jan 30, 2023
Transactions value $: $0
Form type: 4
Date filed: 1/31/2023, 03:09 PM
Previous filing: Oct 13, 2022
Next filing: May 19, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ELOX	Stock Options (Right to Buy)	Award	$0	+2.86K		$0.00	2.86K	Jan 30, 2023	Common Stock	2.86K	$4.00	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option vests as to 50% of the underlying shares on the first anniversary of January 30, 2023, and the remaining 50% of the underlying shares will vest in twelve (12) equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

Remarks:

On December 1, 2022, the Issuer effected a 1-for-40 reverse stock split. The share counts herein have been adjusted to reflect the reverse stock split.